Abstract:Whole-body ischemia and reperfusion due to cardiac arrest and subsequent return of spontaneous circulation constitute post-cardiac arrest syndrome (PCAS), which consists of four syndromes including systemic ischemia/reperfusion responses and post-cardiac arrest brain injury. The major pathophysiologies underlying systemic ischemia/reperfusion responses are systemic inflammatory response syndrome and increased coagulation, leading to disseminated intravascular coagulation (DIC), which clinically manifests as obstruction of microcirculation and multiple organ dysfunction. In particular, thrombotic occlusion in the brain due to DIC, referred to as the "no-reflow phenomenon," may be deeply involved in post-cardiac arrest brain injury, which is the leading cause of mortality in patients with PCAS. Coagulofibrinolytic changes in patients with PCAS are characterized by tissue factor-dependent coagulation, which is accelerated by impaired anticoagulant mechanisms, including antithrombin, protein C, thrombomodulin, and tissue factor pathway inhibitor. Damage-associated molecular patterns (DAMPs) accelerate not only tissue factor-dependent coagulation but also the factor XII- and factor XI-dependent activation of coagulation. Inflammatory cytokines are also involved in these changes via the expression of tissue factor on endothelial cells and monocytes, the inhibition of anticoagulant systems, and the release of neutrophil elastase from neutrophils activated by inflammatory cytokines. Hyperfibrinolysis in the early phase of PCAS is followed by inadequate endogenous fibrinolysis and fibrinolytic shutdown by plasminogen activator inhibitor-1. Moreover, cell-free DNA, which is also a DAMP, plays a pivotal role in the inhibition of fibrinolysis. DIC diagnosis criteria or fibrinolysis markers, including d-dimer and fibrin/fibrinogen degradation products, which are commonly tested in patients and easily accessible, can be used to predict the mortality or neurological outcome of PCAS patients with high accuracy. A number of studies have explored therapy for this unique pathophysiology since the first report on "no-reflow phenomenon" was published roughly 50 years ago. However, the optimum therapeutic strategy focusing on the coagulofibrinolytic changes in cardiac arrest or PCAS patients has not yet been established. The elucidation of more precise pathomechanisms of coagulofibrinolytic changes in PCAS may aid in the development of novel therapeutic targets, leading to an improvement in the outcomes of PCAS patients.

The immunology of the post-cardiac arrest syndrome

The post-cardiac arrest syndrome: A case for lung-brain coupling and opportunities for neuroprotection

Systemic immune responses after ischemic stroke: From the center to the periphery

Acute lung injury and post-cardiac arrest syndrome: a narrative review

Improving Outcomes After Post-Cardiac Arrest Brain Injury: A Scientific Statement From the International Liaison Committee on Resuscitation

Limb Ischemic Postconditioning Alleviates Postcardiac Arrest Syndrome Through the Inhibition of Mitochondrial Permeability Transition Pore Opening in a Porcine Model

Early cytotoxic lymphocyte localization to the brain following resuscitation in a porcine model of asphyxial cardiac arrest: A pilot study

Coagulofibrinolytic Changes in Patients with Post-cardiac Arrest Syndrome

Immune cell expression patterns of CD39/CD73 ectonucleotidases in rodent models of cardiac arrest and resuscitation

Organ-Specific Mitochondrial Alterations Following Ischemia–Reperfusion Injury in Post-Cardiac Arrest Syndrome: A Comprehensive Review

Diverse NKT cells regulate early inflammation and neurological outcomes after cardiac arrest and resuscitation

Management of post-cardiac arrest syndrome

The Involvement of Danger-Associated Molecular Patterns in the Development of Immunoparalysis in Cardiac Arrest Patients

Cardiac Intensive Care Unit Management of Patients After Cardiac Arrest: Now the Real Work Begins

Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two-hit” model

Cardiac arrest and microcirculatory dysfunction: a narrative review

Remote Ischemic Postconditioning Alone and Combined with Therapeutic Hypothermia Improve Neurological Outcomes after Cardiopulmonary Resuscitation in A Porcine Model

Immune dysfunction following severe trauma: A systems failure from the central nervous system to mitochondria

Spontaneous Hypothermia Ameliorated Inflammation and Neurologic Deficit in Rat Cardiac Arrest Models Following Resuscitation

Extracerebral multiple organ dysfunction and interactions with brain injury after cardiac arrest

Cytokine hemoadsorption with CytoSorb® in post-cardiac arrest syndrome, a pilot randomized controlled trial